Kowa Pharmaceuticals America signs co-promotion agreement to promote Arcutis's ZORYVE^®

Client(s) Kowa Company, Ltd.

Jones Day represented Kowa Pharmaceuticals America, Inc. in connection with a co-promotion agreement with Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT). Under the agreement, Kowa will leverage its primary care sales force to market and promote ZORYVE^® (roflumilast) cream and ZORYVE^® (roflumilast) foam to primary care practitioners and pediatricians for all FDA approved indications. Arcutis will maintain responsibility for the marketing and sales of ZORYVE^® to dermatologists, other dermatology clinicians, and related specialists. The partnership is expected to expand the total addressable market for ZORYVE^®, providing access to a large portion of the 7.4 million patients treated outside of dermatology offices.